World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0000929902
Reproduction Date:

Title: Cyclobenzaprine  
Author: World Heritage Encyclopedia
Language: English
Subject: Muscle relaxant, Carisoprodol, Hyoscyamine, Thiocolchicoside, Pizotifen
Collection: Drugs with Unknown Mechanisms of Action, Muscle Relaxants
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)- N,N-dimethyl-1-propanamine
Clinical data
Trade names Amrix (former Flexeril)
  • Category B
Legal status
  • (Prescription only)
Routes of
Pharmacokinetic data
Bioavailability 33% to 55% [1][2]
Metabolism hepatic
Biological half-life 18 hours (range 8–37 hours; n=18)
Excretion renal
CAS Registry Number  Y
ATC code M03
PubChem CID:
DrugBank  Y
ChemSpider  Y
Chemical data
Formula C20H21N
Molecular mass 275.387 g/mol

Cyclobenzaprine, brand names Flexeril among others, is a muscle relaxer medication used to relieve skeletal muscle spasms and associated pain in acute musculoskeletal conditions.[3] It is the best-studied drug for this application.[4] It has also been used off-label for fibromyalgia treatment.[5] A new sublingual formulation of cyclobenzaprine is under development for the chronic management of fibromyalgia syndrome.[6]


  • Medical use 1
  • Side effects 2
    • Overdose 2.1
  • Interactions 3
  • Comparison to other medications 4
  • Formulations 5
  • See also 6
  • References 7

Medical use

After sustaining an injury, muscle spasms may occur to stabilize the affected body part and prevent further damage. They also generate pain. Cyclobenzaprine is FDA-approved to treat such muscle spasms associated with acute, painful musculoskeletal conditions.[3] It decreases pain in the first two weeks,[4][7] peaking in the first few days, but has no proven benefit after two weeks.[4][8] Since no benefit is proven beyond that, therapy should not be continued long-term.[9] It is not useful for spasticity due to neurologic conditions such as cerebral palsy.[9][10]

Cyclobenzaprine has also shown effectiveness in the treatment of fibromyalgia symptoms, with a report of 4.8 patients needing treatment for each (1) patient reporting pain reduction (but no change in fatigue or tender points).[11]

Some experts believe that cyclobenzaprine should be avoided in elderly patients, because it can cause confusion, delerium, and cognitive impairment.[12][13]

Side effects

Meta-analysis studies have found significantly increased rates of drowsiness (38% of patients), dry mouth (24%), dizziness (10%), and adverse events of any kind in patients taking cyclobenzaprine versus placebo.[8] Drowsiness and dry mouth appear to intensify with increasing dose.[14]

The sedative effects of cyclobenzaprine are likely due to its antagonistic effect on histamine, serotonin, and muscarinic receptors. Agitation is a common side effect observed especially in the elderly. In general, the National Committee for Quality Assurance recommends avoiding the use of cyclobenzaprine in the elderly because of the potential for more severe side effects.[15] Treatment protocols and support should follow the same as for any structurally related tricyclic, such as tricyclic antidepressants.[16]


The most common effects of overdose are drowsiness and tachycardia.[3] Rare but potentially critical complications are cardiac arrest, cardiac dysrhythmias, severe hypotension, seizures, and neuroleptic malignant syndrome.[3] Life-threatening overdose is rare,[3] however, as the median lethal dose is about 338 mg/kg in mice and 425 mg/kg in rats.[3] The potential harm is increased when central nervous system depressants and antidepressants are also used; deliberate overdose often includes alcohol among other drugs.[3]


Cyclobenzaprine has major contraindications with monoamine oxidase inhibitors (MAOIs). At least one study also found increased risk of serotonin syndrome when cyclobenzaprine was taken with the serotonergic drugs duloxetine or phenelzine.[17]

These substances may interact with cyclobenzaprine:

If co-administered with opioids, the dose of one or both medicines should be reduced accordingly. The patient should be monitored for excessive sedation.

Comparison to other medications

Cyclobenzaprine has been found to be not inferior to tizanidine, orphenadrine, and carisoprodol in the treatment of acute lower back pain, although none has been proven to be effective for long-term use (beyond two weeks of treatment). No differences in pain or spasm scores were noted among these agents, nor when compared to benzodiazepines.[18] However, nonbenzodiazepine (including cyclobenzaprine) treatment was found to have a lower risk of medication abuse and continuation of use against medical advice. Side effects such as sedation and ataxia are also less pronounced with nonbenzodiazepine antispasmodics.

In a study on the treatment of musculoskeletal pain treatment with cyclobenzaprine alone or in combination with ibuprofen, no significant differences in pain scores were noted among the three treatment groups. Peak benefit was found to occur on day 7 of the treatment for all groups.[19]


Cyclobenzaprine 10mg

Orally, cyclobenzaprine is marketed as Apo-Cyclobenzaprin, Flexeril, Fexmid and Novo-Cycloprine. It is available in generic form. A once-a-day, extended-release formulation, Amrix, is available.[20] Cyclobenzaprine is also used by compounding pharmacies in topical creams.

Cyclobenzaprine is regulated in the U.S. for prescription use only. Though it does not fall within most governmental guidelines as a controlled substance, possession of it without a valid or current prescription may be illegal, depending upon various state and local laws.

Brand names include Flexeril, Amrix, Fexmid, and Mitrul among others.

See also


  1. ^ Micromedex® 2010 – DRUGDEX® Evaluations (Cyclobenzaprine Hydrochloride)
  2. ^ "Cyclobenzaprine Hydrochloride Tablets USP Revised: April 2005 Rx only". 
  3. ^ a b c d e f g "Flexeril (Cyclobenzaprine HCl) Tablets" (pdf).  
  4. ^ a b c Chou R, Peterson K, Helfand M (2004). "Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review". Journal of Pain Symptom Management 28 (2): 140–175.  
  5. ^ "Cyclobenzaprine Hydrochloride" (subscription required). MicroMedex. 5 Feb 2010. Retrieved 16 Feb 2010. 
  6. ^ "Tonix Pharmaceuticals Holding Corp. (TNXP)". 
  7. ^ van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM (2003). Van Tulder, Maurits W, ed. "Muscle relaxants for non-specific low back pain".  
  8. ^ a b Browning R, Jackson JL, O’Malley PG (2001). "Cyclobenzaprine and back pain: a meta-analysis".  
  9. ^ a b c "Cyclobenzaprine official FDA information, side effects, and uses". October 2009. Retrieved 19 Feb 2010. 
  10. ^ Ashby P, Burke D, Rao S; et al. (1972). "Assessment of cyclobenzaprine in the treatment of spasticity". J Neurol Neurosurg Psychiatry 35 (5): 599–605.  
  11. ^ Tofferi JK, Jackson JL, O'Malley PG (15 Feb 2004). "Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis".  
  12. ^ Canadian Agency for Drugs and Technologies in Health; 2015 Feb 23. Long-term Use of Cyclobenzaprine for Pain: A Review of the Clinical Effectiveness. PMID 25763449
  13. ^ Potentially inappropriate medications for the elderly according to the revised Beers criteria. 2012. Duke Clinical Research Institute website.
  14. ^ "Flexeril: Side effects". Retrieved 22 Feb 2010. 
  15. ^ "High risk medications" (pdf).  
  16. ^ Chabria, Shiven B (17 July 2006). "Rhabdomyolysis: a manifestation of cyclobenzaprine toxicity". Journal of Occupational Medicine and Toxicology 1 (1): 16.  
  17. ^ Keegan MT, Brown DR & Rabinstein AA (2006). " 
  18. ^ "Medscape: Medscape Access". 
  19. ^ Childers, M.K.; Petri, M.; Laudadio, C.; Harrison, D.; Silber, S.; Bowen, D. (2004). "Comparison of cyclobenzaprine alone versus cyclobenzaprine plus ibuprofen in patients with acute musculoskeletal spasm and pain". Annals of Emergency Medicine 44 (4): S87.  
  20. ^ "Patient Web site for AMRIX® (Cyclobenzaprine Hydrochloride Extended‐Release Capsules)". 
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.